Trimodal therapy (TMT) involving chemotherapy, radiation, and TURBT is an alternative to radical cystectomy for muscle-invasive bladder cancer. This study analyzed 105 patients treated with TMT to identify optimal candidates. Tumor diameter prior to TURBT was found to be the best predictor of outcomes from TMT. Patients with a tumor diameter ≤3 cm who were eligible for cisplatin chemotherapy had a 79.2% 5-year disease-specific survival rate with TMT, comparable to radical cystectomy. Conversely, patients with a tumor diameter >5 cm had a poor 28.2% 5-year survival rate with TMT regardless of other factors.